# Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-nivo-plus-relatlimab-rela-vs-nivo-in-previously-untreated-metastatic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hussein A. Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Barbara Ratto,Saima Rodriguez,Yuanfang Xu,Sonia Dolfi,Georgina V. Long |
| Citations | 17 |
| DOI | 10.1200/jco.2023.41.16_suppl.9502 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4379281106 |
| Type | conference-abstract |
| Year | 2023 |

## Paper authors

- [Yuanfang Xu](https://scholariq.org/researchers/yuanfang-xu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Paper topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.